KASINGER JAMES R. 4
4 · CRISPR Therapeutics AG · Filed Mar 24, 2025
Insider Transaction Report
Form 4
KASINGER JAMES R.
General Counsel and Secretary
Transactions
- Exercise/Conversion
Common Shares
2025-03-20+6,250→ 84,914 total - Sale
Common Shares
2025-03-21$41.23/sh−3,185$131,318→ 81,729 total - Exercise/Conversion
Restricted Stock Units
2025-03-20−6,250→ 18,750 total→ Common Shares (6,250 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F3]This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.